# AngioDynamics, Inc. (ANGO) · Edgar & Edgarette company card

> AngioDynamics (ANGO) grew revenue 9.5% in FY2026 to $320 million, operating margin -12.5% against a 1.2% median for surgical & medical instruments & apparatus, equity 63.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1275187 · fiscal year ended 2026-05-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ANGO) · [JSON](https://www.pops4.com/boards/company/ANGO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $320M |
| Revenue growth, 1 year | 9.5% |
| Revenue growth per year | 0.3% |
| Operating margin | -12.5% (prior year -13.7%) |
| Net margin | -11.5% |
| Operating cash flow | $3M |
| Capital spending | $3M |
| Free cash flow | $508,000 |
| Cash | $54M |
| Long-term debt | — |
| Total assets | $267M |
| Total equity | $171M |
| Equity ÷ assets | 63.9% |
| Return on equity | -21.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -2.65 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: -3.08 (below the −1.78 line)
- Health Harbor boat: Sound ship · one warning sign · operating loss: a margin of -12.5% in FY2026
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $320.2M (FY2026). Experience: revenue up 9.5% on the year, up 0.3% a year over 4 years; operating margin -12.5%, up from -13.7%. Soundness: equity 63.9% of assets, return on equity -21.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $279.0M and $380.4M next year (method v4.1: its own 5-year record of growth weighed at 57% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $258.0M to $412.7M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -12.5% against a 1.2% median; growth 9.5% against 11.6%.

Range logged 2026-10-09, receipt b4fa7c8afdfdc045, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-11-18 ([filing](https://www.sec.gov/Archives/edgar/data/1275187/000114036126044750/0001140361-26-044750-index.htm))

## Recent filings

- 8-K · filed 2026-11-18 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1275187/000114036126044750/0001140361-26-044750-index.htm)
- 10-Q · filed 2026-10-08 · [filing](https://www.sec.gov/Archives/edgar/data/1275187/000162828026065423/0001628280-26-065423-index.htm)
- DEF 14A · filed 2026-10-08 · [filing](https://www.sec.gov/Archives/edgar/data/1275187/000114036126039022/0001140361-26-039022-index.htm)
- 8-K · filed 2026-10-08 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1275187/000114036126039020/0001140361-26-039020-index.htm)
- 8-K · filed 2026-10-08 · 1.01 Entry into a Material Definitive Agreement; 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1275187/000114036126039019/0001140361-26-039019-index.htm)
- 10-K · filed 2026-07-14 · [filing](https://www.sec.gov/Archives/edgar/data/1275187/000162828026048138/0001628280-26-048138-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001275187.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1275187

## Cite

POPS4, Edgar & Edgarette: AngioDynamics, Inc. (ANGO) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/ANGO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

